Navan beats, raises guidance, buys BoomPop; analysts back it
Big customer win: Evotec Evotec, a global drug discovery company, picked Navan to run travel and expenses across five countries, replacing scattered tools. Each new large customer adds recurring revenue and bookings, which supports the stock because growth in signed business is what investors are watching.
A concrete new enterprise win that feeds the growth story behind the stock.
Q2 beat and guidance raised again Navan's quarterly revenue of about $233 million beat expectations, and it lifted full-year revenue guidance for the second time to roughly $927-933 million. Bookings rose 45% and free cash flow turned positive. Higher expected sales and profit make the shares more valuable.
The core financial result and raised outlook are the main force moving the stock.
BoomPop acquisition: growth vs. cost Navan is buying BoomPop, an AI meetings-and-events platform, for up to $95 million to enter a large untapped spending area. But it adds another integration and is expected to dent operating income in fiscal 2027, only helping profit by 2028. Growth upside, near-term cost drag.
A new deal that both expands the business and weighs on near-term profit.
Analysts name Navan a top pick Needham and Citi both named Navan a top application-software pick, citing high travel demand and underappreciated AI. Analyst endorsements can pull in buyers and support the price, though they are opinions, not company results, so the effect is softer than earnings.
Fresh analyst support that can influence demand for the shares.